Bropirimine is a synthetic agonist for toll-like receptor 7 (TLR7). Bropirimine inhibits differentiation of osteoclast precursor cells into osteoclasts via TLR7-mediated production of IFN-β. Bropirimine is an orally active immunomodulator that has demonstrated anticancer activity in transitional cell carcinoma in situ (CIS) in both the bladder and upper urinary Bropirimine could enhance the transfection efficiency to 2-fold to 5-fold of Lipofectamine 3000 and LNP, all of which are currently approved for clinical use in the treatment of the most common malignant tumors.
Cat.No
DC36761
Name
Bropirimine
Chemical Properties
CAS
Formula
C10H8BRN3O
MW
266.09
Storage
References
Improving lipid nanoparticles delivery efficiency of macrophage cells by using immunomodulatory small molecules-Lirong Yi PhD , Ziyan Zhang MSc-Nanomedicine: Nanotechnology, Biology and Medicine Volume 64, February 2025, 102809
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
